Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average) (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $97.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $97.5 million, up 21.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.5 million (up 21.69% YoY), and the FY2025 annual result was $84.5 million, up 12.59% from the prior year.
• Shares Outstanding (Weighted Average) rose to $97.5 million in Q1 2026 per KYMR's latest filing, from $84.5 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $97.5 million in Q1 2026 and troughed at $51.7 million in Q1 2022.
• A 5-year average of $68.4 million and a median of $70.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) advanced 7.13% in 2023, then gained 28.58% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.9 million in 2022, then grew by 8.22% to $58.4 million in 2023, then gained by 28.58% to $75.0 million in 2024, then advanced by 12.59% to $84.5 million in 2025, then advanced by 15.44% to $97.5 million in 2026.
• Business Quant data shows KYMR's Shares Outstanding (Weighted Average) at $97.5 million in Q1 2026, $84.5 million in Q4 2025, and $82.7 million in Q3 2025.